Sonic Healthcare Ltd banner

Sonic Healthcare Ltd
F:SAB

Watchlist Manager
Sonic Healthcare Ltd Logo
Sonic Healthcare Ltd
F:SAB
Watchlist
Price: 12.596 EUR -0.06% Market Closed
Market Cap: €6.1B

Wall St Price Targets

SAB Price Targets Summary
Sonic Healthcare Ltd

Wall Street analysts forecast SAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SAB is 13.852 EUR with a low forecast of 10.39 EUR and a high forecast of 17.462 EUR.

Lowest Forecast
Price Target
10.39 EUR
18% Downside
Average Forecast
Price Target
13.852 EUR
10% Upside
Highest Forecast
Price Target
17.462 EUR
39% Upside
Sonic Healthcare Ltd Competitors:
Price Targets
DVA
DaVita Inc
-16% Downside
COHU
Cohu Inc
21% Upside
BLFS
BioLife Solutions Inc
9% Upside

Revenue
Forecast

8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
8% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is 6%.

Gross Profit
Forecast

8% / Year
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss
8% / Year
Past Growth
-5% / Year
Estimated Growth
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 8 years is -5%.

Operating Income
Forecast

5% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 8 years is 9%.

Pre-Tax Income
Forecast

5% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
5% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 12%.

Net Income
Forecast

4% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
4% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 8 years is 12%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SAB's stock price target?
Price Target
13.852 EUR

According to Wall Street analysts, the average 1-year price target for SAB is 13.852 EUR with a low forecast of 10.39 EUR and a high forecast of 17.462 EUR.

What is the Revenue forecast for Sonic Healthcare Ltd?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 8%. The projected CAGR for the next 8 years is 6%.

What is the Gross Profit forecast for Sonic Healthcare Ltd?
Projected CAGR
-5%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 8%. The projected CAGR for the next 8 years is -5%.

What is the Operating Income forecast for Sonic Healthcare Ltd?
Projected CAGR
9%

Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 8 years is 9%.

What is the Pre-Tax Income forecast for Sonic Healthcare Ltd?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 5%. The projected CAGR for the next 3 years is 12%.

What is the Net Income forecast for Sonic Healthcare Ltd?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Net Income has been 4%. The projected CAGR for the next 8 years is 12%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett